AstraZeneca (LON:AZN) Stock Crosses Above 200-Day Moving Average – Time to Sell?

AstraZeneca PLC (LON:AZN)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of £112.23 ($144.78) and traded as high as £115.52 ($149.02). AstraZeneca shares last traded at £113.92 ($146.96), with a volume of 1,971,750 shares traded.

Analyst Ratings Changes

A number of equities research analysts have weighed in on AZN shares. Berenberg Bank restated a “buy” rating and set a GBX 140 ($1.81) price target on shares of AstraZeneca in a research report on Wednesday, March 26th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a report on Wednesday, February 19th. Finally, Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of GBX 7,542.80 ($97.30).

AstraZeneca Stock Down 3.0 %

The stock has a market cap of £212.69 billion, a P/E ratio of 30.30, a P/E/G ratio of 0.86 and a beta of 0.17. The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. The company has a 50-day simple moving average of £116.11 and a two-hundred day simple moving average of £112.22.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.